Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Executive Summary

Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.

Advertisement

Related Content

ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price
Aimovig Priced ‘Well Below’ Part D Specialty Threshold To Avoid Coinsurance
Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Praluent Deal Combines Price Break With Point-Of Sale Rebates; Express Scripts Wants To Do More
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
ICER To Open Cost Effectiveness Models To Drug Firms During Review Process
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel